Excessive Daytime Sleepiness (EDS) Market to Reach USD 7.9 Billion by 2034

Excessive Daytime Sleepiness (EDS) is a chronic condition characterized by an inability to stay awake and alert during the day, even with adequate nighttime sleep. It is most commonly associated with narcolepsy, obstructive sleep apnea (OSA), idiopathic hypersomnia, Parkinson's disease, and shift work disorders. EDS significantly impairs cognitive function, work productivity, and quality of life, and increases the risk of accidents.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71903

The global EDS market is driven by rising prevalence of sleep disorders, new drug approvals, and increasing awareness about sleep health. With digital diagnostics, wearable devices, and novel wake-promoting agents entering the market, the outlook for EDS management is rapidly evolving.

Market Overview
• Market Size (2024): USD 4.1 billion
• Forecast (2034): USD 7.9 billion
• CAGR (2025-2034): 6.6%

Growth is fueled by increasing cases of OSA and narcolepsy, pipeline wake-promoting drugs, and adoption of sleep diagnostics.

Key Highlights:
• OSA affects an estimated 900 million people globally, many of whom suffer from EDS.
• FDA-approved drugs such as solriamfetol (Sunosi) and pitolisant (Wakix) strengthen the market.
• Wearable sleep trackers and AI diagnostics expanding consumer adoption.
• Strong clinical trial activity in orexin and dopamine-modulating drugs.

Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Wake-Promoting Agents (Modafinil, Armodafinil, Solriamfetol, Pitolisant)
o Stimulants (Amphetamines, Methylphenidate - limited by safety)
o Adjunctive Therapies (antidepressants for narcolepsy-associated EDS)
• Non-Pharmacological Interventions
o CPAP (Continuous Positive Airway Pressure) for OSA
o Behavioral & Cognitive Therapy
o Lifestyle Modifications (sleep hygiene, diet)
• Diagnostics & Devices
o Polysomnography
o Multiple Sleep Latency Test (MSLT)
o Wearable Devices & AI-Based Sleep Trackers

By Platform:
• Small Molecules (modafinil, solriamfetol, pitolisant)
• Biologics (emerging orexin-based therapies)
• Devices & Digital Tools

By Technology:
• AI-Based Sleep Disorder Diagnostics
• Wearable Sleep Tracking Technology
• Digital Therapeutics for Sleep Disorders

By End Use:
• Hospitals & Sleep Clinics
• Home Care & Digital Platforms
• Research Institutes
• Specialty Neurology Clinics

By Application:
• Narcolepsy-Associated EDS
• OSA-Associated EDS
• Parkinson's Disease-Associated EDS
• Idiopathic Hypersomnia
• Clinical Research

Segmentation Summary:
Pharmacological therapies dominate, but devices, diagnostics, and digital tools are expanding rapidly. Pipeline orexin-based therapies may redefine the future landscape.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71903/excessive-daytime-sleepiness-eds-market

Regional Analysis
North America
• ~44% share in 2024.
• High prevalence of OSA and narcolepsy.
• Strong adoption of solriamfetol and pitolisant.
• Extensive sleep clinic networks.
Europe
• ~29% share.
• Germany, France, and UK leading in CPAP adoption and sleep disorder awareness.
• EMA approvals expanding drug accessibility.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.5%.
• Rising obesity and OSA prevalence in India and China.
• Expanding diagnostic infrastructure and consumer wearables.
Middle East & Africa
• Growing burden of untreated OSA.
• Limited access to advanced drugs but expanding CPAP penetration.
Latin America
• Brazil and Mexico driving regional growth.
• Increasing awareness campaigns about sleep disorders.
Regional Summary:
North America and Europe dominate due to high drug adoption and infrastructure, while Asia-Pacific grows fastest due to obesity-related OSA and consumer tech integration.

Market Dynamics
Key Growth Drivers:
• Rising prevalence of OSA, narcolepsy, and Parkinson's disease.
• Approvals of novel wake-promoting drugs.
• Growth of sleep diagnostic centers and consumer wearables.
• Increasing awareness of sleep health and productivity loss.

Key Challenges:
• Safety and abuse potential of stimulant drugs.
• High cost of novel therapies.
• Underdiagnosis of sleep disorders, particularly in Asia and Africa.
• Limited long-term data on newer agents.

Latest Trends:
• Orexin receptor agonists in development for narcolepsy and EDS.
• Integration of AI and wearables into sleep monitoring.
• Growth of digital therapeutics for insomnia and EDS.
• Telemedicine expansion for sleep medicine consultations.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71903

Competitor Analysis
Major Players in the Market:
• Jazz Pharmaceuticals plc (Xyrem, Xywav for narcolepsy-related EDS)
• Harmony Biosciences (Wakix - Pitolisant)
• Axsome Therapeutics, Inc.
• Teva Pharmaceutical Industries Ltd. (Modafinil, Armodafinil)
• Takeda Pharmaceutical Company Limited
• Avadel Pharmaceuticals (LUMRYZ - once-nightly oxybate)
• ResMed Inc. (CPAP devices)
• Philips Healthcare (sleep diagnostics, CPAP)
• Fitbit (Google) & Apple Inc. (wearable sleep trackers)
• Idorsia Pharmaceuticals Ltd. (orexin pipeline therapies)

Competitive Summary:
Jazz and Harmony Biosciences dominate narcolepsy-related EDS. Teva leads with generics, while ResMed and Philips dominate CPAP and diagnostics. Apple and Fitbit drive consumer adoption of wearable sleep health tools. Idorsia leads in orexin pipeline therapies.

Conclusion
The Excessive Daytime Sleepiness (EDS) Market, valued at USD 4.1 billion in 2024, is projected to reach USD 7.9 billion by 2034, growing at a CAGR of 6.6%. Rising sleep disorder prevalence, drug approvals, and digital diagnostics are reshaping the market.

Key Takeaways:
• Pharmacological therapies dominate but face safety and cost challenges.
• North America and Europe lead adoption, while Asia-Pacific grows fastest.
• Wearables and AI-driven tools expand patient monitoring.
• Orexin-based therapies represent the future of EDS treatment.

The next decade will transform EDS care from stimulant-based therapies to integrated pharmacological, digital, and device-driven management, creating strong opportunities for pharma, medtech, and digital innovators.

This report is also available in the following languages : Japanese (日中の過度の眠気(EDS)市場), Korean (과도한 주간 졸음증(EDS) 시장), Chinese (日间过度嗜睡症(EDS)市场), French (Marché de la somnolence diurne excessive (SDE)), German (Markt für übermäßige Tagesmüdigkeit (EDS)), and Italian (Mercato della sonnolenza diurna eccessiva (EDS)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71903/excessive-daytime-sleepiness-eds-market#request-a-sample

Our More Reports:

Biotechnology Market
https://exactitudeconsultancy.com/reports/72399/biotechnology-market

Cannab Market
https://exactitudeconsultancy.com/reports/72398/market

Medical Tourism Market
https://exactitudeconsultancy.com/reports/72397/medical-tourism-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.